Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

ANA773 and two receiving placebo in each cohort. There was a statistically significant decrease in viral load in the group dosed at 1600 mg compared to placebo, although not all patients at this dose demonstrated a decrease in viral load. One patient at 1600 mg demonstrated a nadir response of 0.8 log10 decline with an end-of-treatment response of 0.7 log10; a second patient demonstrated a nadir response of 1.1 log10 decline and an end-of-treatment response of 0.5 log10; and a third patient demonstrated a nadir response of 2.5 log10 decline and an end-of-treatment response of 2.2 log10. No serious adverse events have been reported and there were no discontinuations from the patient portion of this study. In an earlier segment of the study, dosing in healthy volunteers showed evidence of immune induction starting at 800 mg. Tolerability in healthy volunteers was generally good, with no serious adverse events. An increased incidence of interferon-like side effects was seen at the 1200 and 1600 mg dose levels, with one discontinuation at 1200 mg and two discontinuations at 1600 mg. The pharmacokinetic (PK) and pharmacodynamic (PD) data from the healthy volunteer portion of the Phase I Clinical Trial of ANA773 in HCV are being presented in a poster at EASL titled, "PK/PD Assessment of a Phase I Healthy Volunteer with ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, for the Treatment of HCV."

  • Phase I Clinical Trial in Oncology. Anadys continues to enroll patients in a Phase I study of ANA773 in oncology. The Company is currently dosing ANA773 at 800 mg, administered every other day.

Webcast of Conference Call

Anadys will host a conference call at 5:00 pm Eastern Daylight Time today to discuss its first quarter 2009 financial results and highlights and to provide an update on its deve
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... year to bring together supply chain risk management and resiliency practitioners with luminaries ... and share best practices, and be recognized for their innovations and performance excellence. ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... of its properties such as low carbon footprints and compostability. These properties can ... petroleum based plastics. On the basis of applications, the market for biodegradable plastics ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... market is estimated at $0.17 billion by 2018 at ... The near future will bring Biomedical sensors that ... These sensors can be set to trigger alerts when ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Israel Biomedical Sensors Market - Growth, Trends & Forecasts ... The Israel Biomedical Sensors market is estimated at $0.19 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... Entrepreneur Anthony ... Directors, IRVINE, Calif., Sept. 5 NeoMatrix, developer of ... to,identify breast cancer risk, announced today that the company has ... enable an expanded,market release of the HALO System, which is ...
... Sept. 5 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) ... the Bear Stearns 20th Annual Healthcare Conference on September,11, ... Time) at the Grand,Hyatt Hotel in New York City. ... to provide a corporate overview of the,company and its ...
... the Key Problems Faced by Insomniacs, i.e.,Sleep Onset and ... Today at 11:00 am CET (10:00 am UK,time, 5:00 ... Congress in,Australia HAMBURG, Germany and OXFORD, England, September ... the worldsleep07 congress in Cairns, Australia the,details of the ...
Cached Biology Technology:NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 2NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 3NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test 4Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 2Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 3Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015  Sarcos ... today it will unveil its "Guardian S" snake robot, ... National Tactical Officers Association Conference on August 30 in ... is the first-ever commercially available energetically autonomous snake robot, ... in-field trials and is protected by more than 50 ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... N.Y., May 13 bioMETRX, Inc. (OTC,Bulletin Board: ... today announced that it has filed 5 new ... Office., The products covered by the filings ... portable luggage and mailboxes. The,traditional products that are ...
... P. Nelson, of West Orange, received the Kenneth R. ... on May 5th for promoting unity among engineering societies. ... NJIT ( www.njit.edu ) coupled with earlier leadership positions ... arrived at NJIT in 2005 after spending more than ...
... New Hampshire Glycomics Center have helped identify a specific ... a glycoprotein antibody that could lead to improved ... The study, reported in a recent edition of the ... Rockefeller University. The work revolves around immunoglobulin ...
Cached Biology News:bioMETRX, Inc. Files for Several New Patents 2NJIT Provost Priscilla P. Nelson honored at National Academy of Engineering 2Sugar linkage could lead to better treatment for autoimmune diseases 2
... Clone/PAD: ZMD.283. Immunogen: Fusion protein ... Specific for ASIP/PAR-3 (atypical PKC isotype-specific ... antigen is not related to the ... Human Dog Xenopus (positive controls: Caco-2 ...
...
Request Info...
normal rat IgM AF647...
Biology Products: